Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update
Initiated three clinical trials in 2017 and on track to deliver three additional development programs in 2018
Neurology pipeline growing; candidate in spinocerebellar ataxia type 3 to be named by year end 2018
“2017 was a transformative year for Wave as we transitioned into clinical development by initiating trials for our three lead neurology programs, established our in-house manufacturing capability and made great progress on delivering three more neurology development programs in 2018,” said
Business Summary and Update
- Global strategic collaboration with Takeda to advance therapies for central nervous system (CNS) disorders
February 2018, Wave formed a global strategic collaboration with Takeda Pharmaceutical Company Limited(Takeda) to discover, develop, and commercialize nucleic acid therapies for disorders of the CNS. Under the terms of the agreement, Takeda is obligated to make an initial payment of $110 millionto Wave and purchase $60 millionof Wave’s ordinary shares at $54.70per share. Takeda is also required to fund at least $60 millionof Wave research over a four-year period to advance multiple preclinical targets. Wave’s collaboration agreement with Takeda will become effective upon satisfaction of customary closing conditions, including the requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Preclinical in vivo data supporting amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) programs presented at 28th International Symposium on ALS/MND
December 2017, Wave announced data from preclinical studies of WVE-3972-01, the company’s investigational stereopure antisense oligonucleotide designed to target the pathogenic allele of the C9ORF72 gene for the treatment of ALS and FTD. In preclinical in vivo studies, WVE-3972-01 demonstrated a potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD.
- Neurology pipeline continues to progress and expand across multiple diseases
Expanding the neurology pipeline into spinocerebellar ataxia type 3 (SCA3)
Wave announced today that it expects to name a potential candidate targeting the ATXN3 gene for the treatment of SCA3 by the end of 2018. This new program will add to Wave’s current and planned clinical neurology development programs in Huntington’s disease (HD), Duchenne muscular dystrophy (DMD), ALS, and
SCA3, also known as Machado–Joseph disease, is caused by a CAG-repeat expansion in the ATXN3 gene, resulting in an abnormally long polyglutamine stretch in the encoded ataxin-3 protein. Mutant ataxin-3 protein is thought to cause widespread neuronal loss in the brain and spinal cord, likely through a toxic gain of function mechanism. SCA3 is the most common dominantly inherited form of ataxia. The prevalence of SCA3 is believed to be one to two cases in 100,000 people with significant geographic and ethnic variations. There are currently no therapies approved for the treatment of SCA3.
HD: WVE-120101 and WVE-120102
The PRECISION-HD program, which includes two global Phase 1b/2a clinical trials evaluating WVE-120101 and WVE-120102 for patients with HD, continues to enroll patients and the company is on track to report topline data in H1 2019.
Wave’s two programs are allele-specific and differentiated from other investigational therapies currently being studied for the treatment of HD. WVE-120101 and WVE-120102 are designed to selectively silence mRNA transcript produced by the disease-causing mutant huntingtin (HTT) allele. This personalized approach reduces the mutant HTT protein while leaving the healthy HTT mRNA transcript relatively intact. The healthy transcript is required to produce wild-type, or healthy, HTT protein which is critical for neuronal function, as evidenced by multiple preclinical studies indicating that long-term suppression of healthy HTT protein may have detrimental consequences. Wave’s allele-specific approach may also enable the company to address the pre-manifest, or asymptomatic, HD patient population in the future.
Wave continues to advance its research and clinical efforts in neuromuscular diseases, including WVE-210201, currently in a global Phase 1 clinical trial for the treatment of DMD patients amenable to exon 51 skipping. Safety data from the trial are anticipated in Q3 2018 and expected to facilitate the rapid transition to an open-label extension study and efficacy study. Both studies following the Phase 1 are designed to include an interim efficacy readout of dystrophin expression from muscle biopsies in H2 2019.
FTDand exon 53 DMD programs on track to transition to development in 2018
The company intends to initiate clinical trials of WVE-3972-01 in ALS and
FTDin Q4 2018. Wave’s next DMD development program will target exon 53, with clinical trials expected to initiate in Q1 2019.
- New in vivo data support ophthalmology franchise
Wave is advancing the development of stereopure oligonucleotides to target genetic ophthalmologic diseases, with an initial emphasis on retinal diseases. Using the long-noncoding RNA MALAT1 as a proof-of concept target, a 10-fold increase in potency was achieved in vivo with a stereopure oligonucleotide as compared to a stereorandom oligonucleotide following a single intravitreal injection in the back of a mouse eye. The knockdown of MALAT1 RNA was sustained through three months after the single injection and the study is scheduled to continue for a total of six months.
In addition, recent results from a preclinical in vivo study in non-human primates demonstrated that a stereopure oligonucleotide achieved a clear dose-dependent knockdown of MALAT1 mRNA in the back of the eye one week following a single intravitreal injection. A six-month duration of effect study is planned.
Wave is conducting additional research to develop stereopure oligonucleotides against specific genetic targets to treat diseases of the eye.
- Pfizer collaboration progress
November 2017, Wave achieved a milestone under its collaboration with Pfizer by demonstrating significant activity of stereopure GalNAc-conjugated APOC3 antisense oligonucleotides over stereorandom oligonucleotides in in vivo studies and meeting other milestone criteria. The collaboration continues to make progress on developing genetically targeted therapies for the treatment of metabolic diseases, such as nonalcoholic steatohepatitis.
Fourth Quarter and Full Year 2017 Financial Results and Financial Guidance
Wave reported a net loss of
Research and development expenses were
General and administrative expenses were
Wave ended 2017 with
The company expects that its cash and cash equivalents, together with the committed cash from its collaboration with Takeda, which is expected to close in the first quarter of 2018, have the potential to fund its operating and capital expenditure requirements to the end of 2020.
This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated commencement, data readouts and duration of our clinical trials; the protocol, design and endpoints of our clinical trials; the future performance and results of our programs in clinical trials; the progress and potential benefits of our collaborations with partners, including the expected timing of when our collaboration with Takeda will take effect; the potential of our in vitro and in vivo preclinical data to predict the behavior of our compounds in humans in clinical trials; our identification of future candidates and their therapeutic potential; the anticipated therapeutic benefits of our potential therapies compared to others; our advancing of therapies across multiple modalities and the anticipated benefits of that strategy; the anticipated benefits of our manufacturing process and our internal manufacturing facility; our future growth; the potential benefits of our stereopure compounds compared to stereorandom compounds, our drug discovery platform and nucleic acid therapeutics generally; and the anticipated duration of our cash runway. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the following: the ability of our preclinical programs to produce data sufficient to support our clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results of our programs, which may not support further development of product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to finance our drug discovery efforts and to raise additional capital when needed; and competition from others developing therapies for similar uses, as well as the information under the caption “Risk Factors” contained in our most recent Annual Report on Form 10-K filed with the
UNAUDITED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
|December 31, 2017||December 31, 2016|
|Cash and cash equivalents||$||142,503||$||150,293|
|Prepaid expenses and other current assets||7,985||1,483|
|Deferred tax assets||—||214|
|Total current assets||150,488||151,990|
|Property and equipment, net||27,334||8,607|
|Deferred tax assets||—||560|
|Total long-term assets||31,355||12,821|
|Liabilities, Series A preferred shares and shareholders’ equity|
|Accrued expenses and other current liabilities||8,898||4,434|
|Current portion of capital lease obligation||16||62|
|Current portion of deferred rent||60||—|
|Current portion of deferred revenue||2,705||2,705|
|Current portion of lease incentive obligation||344||11|
|Total current liabilities||19,621||12,155|
|Capital lease obligation, net of current portion||—||16|
|Deferred rent, net of current portion||4,214||680|
|Deferred revenue, net of current portion||5,607||8,311|
|Lease incentive obligation, net of current portion||3,094||116|
|Total long-term liabilities||14,534||9,919|
|Series A preferred shares, no par value; 3,901,348 shares issued and outstanding||$||7,874||$||7,874|
| Ordinary shares, no par value; 27,829,079 and 23,502,169 shares issued and
outstanding at December 31, 2017 and 2016, respectively
|Additional paid-in capital||22,172||10,029|
|Accumulated other comprehensive income (loss)||116||(291)|
|Total shareholders’ equity||139,814||134,863|
|Total liabilities, Series A preferred shares and shareholders’ equity||$||181,843||$||164,811|
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
|For the Year Ended December 31,|
|Research and development||79,309||40,818||9,057|
|General and administrative||26,975||15,994||10,393|
|Total operating expenses||106,284||56,812||19,450|
|Loss from operations||(102,580)||(55,327)||(19,298)|
|Other income (expense), net:|
|Interest income (expense), net||6||337||86|
|Other income (expense), net||(331)||(50)||56|
|Total other income (expense), net||1,253||542||142|
|Loss before income taxes||(101,327)||(54,785)||(19,156)|
|Income tax provision||(708)||(616)||(44)|
|Net loss per share attributable to ordinary
shareholders—basic and diluted
|Weighted-average ordinary shares used in computing
net loss per share attributable to ordinary
shareholders—basic and diluted
Source: Wave Life Sciences